Summary
Professor Ko Kato (CDG) and his group at NAIST (President: Dr. Kazuhiro Shiozaki) has developed the translation enhancer that enhances the expression of heterologous proteins in plants.
NAIST has assigned the rights to Medicago Inc. for the production of a plant-derived COVID-19 vaccine for the prevention of novel coronavirus infection (COVID-19), and the results are being used by Medicago Inc. to improve production efficiency.
For more information, click here.
Development of Technology for High Expression of Heterologous Proteins in Plants – Application to Plant-derived COVID-19 Vaccine
